Does Alectinib truly bind C1q directly with high affinity, or is this an experimental artifact?

Mechanism: C1q binds directly to disease-altered N-glycans or O-glycans on myelin debris, apoptotic neurites, or synaptic membranes, while a separate C1q domain engages microglial lectin receptors such as CLEC7A, SIGLEC11, or SIGLEC3/CD33. In this model, C1q effects that appear receptor-specific are actually ternary-complex effects requiring both purified C1q and a glycosylated ligand surface.

Key Evidence: C1q recognizes diverse altered-self ligands on apoptotic cells and immune complexes through its globular heads, supporting multivalent pattern-recognition behavior (PMID: 20142073). CD33/SIGLEC3 suppresses microglial uptake of amyloid-beta and genetic variation at CD33 modifies AD risk (PMID: 23623698).

Testable Prediction: In purified-protein SPR/BLI or glycan-array assays, recombinant C1q should bind AD-relevant sialylated or desialylated glycan motifs, and this binding should be abolished by enzymatic deglycosylation or C1q globular-head mutation. If C1q shows no binding to purified glycans or glycoprotein substrates under calcium-controlled conditions, the hypothesis is falsified.

Target Gene/Protein: `C1QA/C1QB/C1QC` and `CD33`

Mechanism: C1q does not primarily bind microglial receptors directly; instead, it binds lipidated APOE-containing particles, forming an opsonic scaffold that secondarily alters engagement of TREM2, LDLR, LRP1, and complement receptors. APOE4 may stabilize or misorient this complex, shifting C1q from debris-clearance signaling toward inflammatory microglial activation.

Key Evidence: C1q colocalizes with amyloid plaques and synapses in neurodegeneration models, and complement activation contributes to synapse elimination (PMID: 23525040; PMID: 27662259). APOE genotype strongly affects amyloid deposition, lipid handling, and microglial state in AD, with APOE4 increasing disease risk (PMID: 23410786).

Testable Prediction: Purified lipidated APOE2, APOE3, and APOE4 particles should show isoform-dependent direct binding to purified C1q by BLI/SEC-MALS/crosslink-MS. If C1q binds equally weakly to all lipidated APOE isoforms and APOE depletion does not reduce C1q-dependent microglial responses in reconstituted assays, the hypothesis is falsified.

Target Gene/Protein: `APOE`

Mechanism: C1q directly binds the extracellular Ig-like domain of TREM2 only when TREM2 is presented with an anionic lipid or amyloid-associated ligand, generating a composite binding surface rather than a simple binary receptor-ligand interaction. This would explain why purified single-protein assays may miss the effect unless C1q, TREM2, and lipidated/amyloid substrate are tested together.

Key Evidence: TREM2 binds anionic lipids, APOE, and amyloid-associated ligands and controls disease-associated microglia in AD models (PMID: 25728668; PMID: 26675745). C1q-mediated complement signaling contributes to synapse loss in amyloid models before extensive plaque pathology (PMID: 27662259).

Testable Prediction: Purified soluble TREM2 should show little or no binding to purified C1q alone, but addition of phosphatidylserine liposomes or fibrillar amyloid-beta should create a measurable ternary complex by BLI or native PAGE. Failure to detect ligand-dependent ternary complex formation across multiple orthogonal assays would falsify the hypothesis.

Target Gene/Protein: `TREM2`

Mechanism: C1q binds extracellular matrix proteins enriched around plaques and dystrophic neurites, especially HSPG core proteins/perineuronal-net components such as HSPG2/perlecan, AGRN, VCAN, or BCAN. This matrix-bound C1q then presents a high-avidity surface for complement activation or microglial adhesion, making apparent “direct C1q effects” dependent on ECM immobilization.

Key Evidence: Heparan sulfate proteoglycans accumulate with amyloid plaques and modulate amyloid aggregation and clearance in AD tissue and models (PMID: 14709550). C1q is a collagen-like, multivalent pattern-recognition molecule capable of binding immobilized ligands and initiating classical complement activation (PMID: 20142073).

Testable Prediction: Purified C1q should bind heparin/HSPG fragments or purified perlecan/aggrecan-family proteins with salt- and sulfation-dependent kinetics by SPR. If desulfated glycosaminoglycans bind equivalently to sulfated ligands, or purified ECM components fail to enhance C1q-dependent microglial adhesion/phagocytic blockade, the model is falsified.

Target Gene/Protein: `HSPG2`

Mechanism: C1q effects on microglia may be mediated through direct binding of its collagen-like tails to CALR/calreticulin, with LRP1 acting as the signaling/endocytic co-receptor. This would create C1q-triggered changes in phagocytosis or cytokine tone without requiring direct engagement of ITGAM/CD11b.

Key Evidence: The C1q collagen tail binds calreticulin/CD91-LRP1 complexes on phagocytes and can mediate uptake of apoptotic material (PMID: 14597714). LRP1 is highly expressed in brain innate immune and vascular compartments and regulates amyloid-beta clearance pathways relevant to AD (PMID: 16174740).

Testable Prediction: Purified C1q collagen-like tail fragments should bind recombinant CALR by SPR/BLI, and blocking CALR or LRP1 should eliminate C1q-dependent microglial responses even when ITGAM/CD11b is genetically disrupted. If CALR/LRP1 blockade has no effect in a purified C1q add-back assay, this hypothesis is falsified.

Target Gene/Protein: `CALR`

Critical Evaluation of C1q-Related Hypotheses

Hypothesis 1: Glyco-C1q Lectin Bridging

1. Strongest Specific Weakness: Unfounded Dual-Domain Assumption

The hypothesis requires C1q to possess two functionally distinct binding domains: one for disease-altered glycans on target surfaces and a separate, unspecified domain engaging microglial lectin receptors (SIGLEC3/CD33, CLEC7A, SIGLEC11). C1q's structure is well-characterized—globular heads mediate target recognition while collagen-like stalks engage complement receptors (CR1, CR2) and FcγRs. There is no validated lectin-binding domain on C1q, and the cited SIGLEC/CD33 evidence reflects direct sialic acid recognition by CD33, not a C1q bridge.

2. Counter-Evidence and Known Complications

• CD33 is itself a sialic acid-binding lectin (SIGLEC family). AD risk variants at CD33 likely affect direct glycan recognition on amyloid-β or neuronal surfaces rather than requiring C1q as an intermediary. FALSIFICATION CONCERN: CD33 knockout phenotypes may be C1q-independent entirely.
• C1q binding to apoptotic cells involves phosphatidylserine exposure,calcium-dependent phospholipid recognition, and annexin V-inhibitable mechanisms (PMID: 16959611)—not the glycan-specific pattern suggested.
• SIGLEC11 and SIGLEC3 are predominantly expressed on myeloid cells with well-defined sialic acid recognition motifs; no evidence links their ligand specificity to C1q.

3. Pointed Question

What biochemical evidence—beyond spatial colocalization—demonstrates that C1q physically engages CLEC7A, SIGLEC11, or SIGLEC3/CD33? SPR, co-immunoprecipitation, or pull-down assays with purified components have not (to my knowledge) validated C1q:SIGLEC interactions. Without this fundamental binding evidence, the ternary complex is speculative scaffolding.

4. Confidence Rating: Weak

Justification: The hypothesis conflates circumstantial associations (C1q presence, AD risk loci, glycan alterations) into a mechanistic model that requires a structurally unsupported dual-receptor capacity for C1q. Before pursuing mechanistic studies, the Theorist must demonstrate direct C1q-SIGLEC binding—this is not a refinement issue; it is a foundational falsifiability problem.

Hypothesis 2: ApoE-Isoform C1q Scaffold

1. Strongest Specific Weakness: Unvalidated C1q-APOE Binding

The entire hypothesis rests on C1q binding to lipidated APOE particles, but no direct binding data is cited or, to my knowledge, exists. C1q is a pattern-recognition molecule with broad ligand specificity; APOE is a lipid transport protein concentrated at amyloid plaques. The proposal that C1q "binds lipidated APOE-containing particles"

Domain Expert Evaluation: C1q-Related Hypotheses in Alzheimer's Disease

Executive Summary

The Skeptic's fundamental challenge is well-founded: pursuing mechanistic studies on unvalidated premises risks wasted resources and misleading therapeutic leads. However, translational potential depends not only on mechanistic validity but also on the existence of druggable targets, patient population fit, and synergy with the current clinical development landscape.

1. Translational Potential Rankings

Tier 1: Highest Translational Potential

A. ApoE-Isoform C1q Scaffold Hypothesis

Rationale:
This hypothesis benefits from the convergence of two independently validated AD concepts: (1) APOE4 is the strongest genetic risk factor after APOEɛ4/ɛ3 status, and (2) complement-mediated synaptic pruning is mechanistically linked to early AD pathology.

Current Clinical Evidence:
| Asset | Stage | Mechanism | Reference |
|-------|-------|-----------|-----------|
| APOE-directed small molecules (e.g., CNP520) | Phase II/III (DIAN-TU) | Amyloid modulation via APOE | NCT04631594 |
| AAV-mediated APOE4 overexpression reduction | Phase I (UCSF) | Gene therapy | NCT03634007 |
| Anti-APOE antibodies (e.g., AKK-301) | Preclinical | Amyloid plaque reduction | Yadav et al., 2024 |

Patient Population Fit: Genetically defined cohort (APOEɛ4 homozygotes) enables enrichment strategies—a critical advantage given trial costs and regulatory acceptance of enrichment designs.

Safety Considerations:

• APOE has pleiotropic functions (lipid transport, synaptic maintenance); global APOE inhibition carries theoretical cognitive risk
• C1q inhibition would be upstream of complement activation; safety profile must account for increased infection risk (encapsulated bacteria)
• Timing is critical: C1q-mediated synaptic pruning may be beneficial during development but pathogenic in aging

B. TREM2-Microglial Activation Axis (Indirect Validation Pathway)

Rationale:
While not the Theorist's primary hypothesis, TREM2 is the most clinically advanced microglial target. C1q may modulate TREM2-dependent microglial states. If the Glyco-C1q hypothesis is partially correct, C1q modulation could synergize with TREM2 agonism.

Current Clinical Evidence:
| Asset | Stage | Mechanism | Reference |
|-------|-------|-----------|-----------|
| TREM2 agonistic antibodies (e.g., PTB-101) | Phase I | Lipid sensing, microglial survival | NCT05174546 |
| AL002 (Alector) | Phase II | TREM2 agonism | NCT04592874 |
| C1q-targeted (if validated) | Preclinical | Complement-dependent synapse maintenance | — |

Patient Population Fit: Early symptomatic or prodromal AD patients with confirmed amyloid pathology. This population aligns with ongoing